Dioscin reduces ovariectomy-induced bone loss by enhancing osteoblastogenesis and inhibiting osteoclastogenesis

详细信息    查看全文

• 作者：Xufeng Tao ; Yan Qi ; Lina Xu ; Lianhong Yin ; Xu Han ; Youwei Xu ; Changyuan Wang ; Huijun Sun ; Jinyong Peng ; ^{jinyongpeng2005@163.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Akt ; protein kinase B ; ALP ; alkaline phosphatase ; AP-1 ; transcription activator ; BMD ; bone mineral density ; DPD ; deoxypyridinoline ; COL1A2 ; collagen ; type I ; alpha 2 ; Cr ; creatinine ; H&E ; hematoxylin-eosin ; HOP ; hyroxyproline ; MyD88 ; myeloid differentiation primary response gene (88) ; MAPKs ; mitogen activated protein kinases ; NFATc1 ; nuclear factor of activated T cells ; NF-κB ; nuclear factor-κB ; OC ; osteocalcin ; OPG ; osteoprotegerin ; OVX ; ovariectomy ; RANKL ; receptor activator for nuclear factor
• 刊名：Pharmacological Research
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：108
• 期：Complete
• 页码：90-101
• 全文大小：5712 K

文摘

Our previous studies showed that dioscin can promote osteoblasts proliferation and differentiation in vitro, but its anti-osteoporosis effect in vivo and the underlying mechanisms remain unclear. In the present work, the results showed that dioscin significantly increased the viability of MC3T3-E1 cells, ALP level and alizarin red S staining area, markedly decreased the numbers of RANKL-induced TRAP-positive multinucleated cells and bone resorption pits formation, enhanced the levels of some osteogenic markers including COL1A2, ALP and OC, which suggested that dioscin clearly promoted osteoblasts proliferation and suppressed osteoclasts formation. In vivo experiments demonstrated that dioscin obviously reduced OVX-induced body weight increase, and improved the biochemical indexes including ALP, StrACP, OC, DPD/Cr, HOP/Cr, BMD, biomechanics and microarchitecture. Moreover, H&E, TB, TRAP staining, and fluorescent double labeling tests indicated that dioscin enhanced osteoblastogenesis and inhibited osteoclastogenesis. Further researches demonstrated that dioscin promoted osteoblastogenesis through up-regulating OPG/RANKL ratio, and inhibited osteoclastogenesis through down-regulating the levels of RANKL induced TRAF6 and the downstream signal molecules including MAPKs, Akt, NF-κB, AP-1, cathepsin K and NFATc1. In addition, dioscin also inhibited TLR4/MyD88 pathway to decrease the levels of TRAF6 and the related proteins. These findings provide new insights to elucidate the effects of dioscin against OVX-induced bone loss, which should be developed as a potential candidate for treating postmenopausal osteoporosis in the future.